Global Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market, By Indication (Respiratory disorders, Oncology, hepatology, Anti-aging, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market Analysis and Size
The huge adoption of unhealthy lifestyle such as lack of physical activity and consumption of tobacco products increases the risk of developing severe diseases such as cancer and asthma which can be treated with therapeutic agents such as MAPK inhibitors which in turn increases the growth of mitogen-activated protein kinase (MAPK) inhibitors therapeutics market. The huge advances in biotechnology and bioinformatics have allowed the researchers to identify genes or pathways that have a vital role in the development and progression of this disease.
Data Bridge Market Research analyses a growth rate in the mitogen-activated protein kinase (MAPK) inhibitors therapeutics market in the forecast period 2023-2030. The expected CAGR of mitogen-activated protein kinase (MAPK) inhibitors therapeutics market is tend to be around 6.60% in the mentioned forecast period. The market is valued at USD 61.4 billion in 2022, and it would grow upto USD 102.38 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Respiratory disorders, Oncology, hepatology, Anti-aging, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GEn1E Lifesciences Inc (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Lilly (U.S.), AstraZeneca (U.K.), Merck & Co., Inc. (U.S.), HepaRegeniX GmbH (Germany), GSK plc (U.K.), Mereo Biopharma Group PLC (U.K.), Kura Oncology, Inc (U.S.), eFFECTOR Therapeutics, Inc (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Mitogen-activated protein kinase (MAPK) signaling pathways is a network which plays a major role in regulating number of physiologic activities of cellular process that includes cell proliferation, apoptosis and inflammatory response. For patients suffering from the cancer associated with mutant gene often results in the hyper activation of MAPK signaling that ultimately increases the cancer cells proliferation and diseases progression. Apart from melanoma, numerous clinical trials are ongoing evaluating MEK inhibitors' role in other cancers including breast cancer, thyroid cancer, ovarian cancer, non-small cell lung cancer, and others.
Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market Dynamics
Drivers
- Works as an Immunity Booster
Mitogen-activated protein kinase (MAPK) inhibitors are widely used in patients, especially in the elderly population and this in turn boosts the market growth. Mitogens are non-specific stimulants of immune cells. Mitogen stimulation which leads to immune cell activation and is widely used as a measure of general immune function. Common mitogens include phorbol-myristic-acid-calcium ionophore (PMA), phytohemagglutinin (PHA), pokeweed mitogen, and others. Thus, this factor boosts the market growth.
Opportunities
- Usage in Chronic Diseases
The wide usage of mitogen-activated protein kinase (MAPK) inhibitors therapeutics in preventing or controlling chronic diseases such as diabetes and hypertension is assisting in increasing the market growth. For instance, the total incidence of hypertension among adults in India is about 30% with urban incidence of 34% and rural prevalence of 28%. In U.S., about 103 million adults have high blood pressure, according to the new statistics from the American Heart Association. This as a result, increases the demand for the market.
- Increasing Healthcare Expenditure And Government Support
The increasing awareness for the disease and associated treatment is also expanding with the growing prevalence of cancer. Numerous government initiatives tend to provide better and more convenient treatments combined with favourable reimbursement policies that are expected to increase the industry growth. Additionally, increasing acceptance of advanced therapies is projected to drive the market.
Restraints/Challenges
- High Cost of Treatment
The rising expenditure associated with the medications impede the market growth. Several genetic drugs cost high, and people in developing and underdeveloped countries cannot at all times afford the treatment process. This hinders the market growth.
This mitogen-activated protein kinase (MAPK) inhibitors therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the mitogen-activated protein kinase (MAPK) inhibitors therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market Scope
The mitogen-activated protein kinase (MAPK) inhibitors therapeutics market is segmented on the basis of indication, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Respiratory Disorders
- Oncology
- hepatology
- Anti-aging
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market Regional Analysis/Insights
The mitogen-activated protein kinase (MAPK) inhibitors therapeutics market is analyzed and market size insights and trends are provided by drugs, indication, route of administration, end-user and distribution channel as referenced above.
The major countries covered in the mitogen-activated protein kinase (MAPK) inhibitors therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for mitogen-activated protein kinase (MAPK) inhibitors therapeutics market throughout the forecasted period because of the high incidence rate of respiratory disorders, increasing awareness and development activities that targets mitogen-activated protein kinase (MAPK) signalling pathways.
Asia-Pacific dominates the market because of increasing presence of refined clinical facilities and growth in better treatment facilities for patients suffering from the chronic conditions. Also, the healthy improvement in healthcare infrastructure and untampered economic boost the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market Share Analysis
The mitogen-activated protein kinase (MAPK) inhibitors therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to mitogen-activated protein kinase (MAPK) inhibitors therapeutics market.
Key players operating in the mitogen-activated protein kinase (MAPK) inhibitors therapeutics market include:
- GEn1E Lifesciences Inc (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Lilly (U.S.)
- AstraZeneca (U.K.)
- Merck & Co., Inc. (U.S.)
- HepaRegeniX GmbH (Germany)
- GSK plc (U.K.)
- Mereo Biopharma Group PLC (U.K.)
- Kura Oncology, Inc (U.S.)
- eFFECTOR Therapeutics, Inc (U.S.)
SKU-